The prevalence of hidradenitis suppurativa (HS) in the pediatric population is unknown. We sought to establish standardized overall as well as gender-, age-, and race-specific prevalence estimates of HS among children and adolescents in the United States. We performed a cross-sectional analysis in a heterogeneous sample of 55 million patients across all census regions. We identified 1,240 patients with HS in whom the ratio of girls to boys was 3.8:1. Almost all (96.8%) patients with HS were ≥10 years of age. Overall, HS prevalence was 0.028%, or 28.1 (95% confidence interval [CI] 26.5-29.7) per 100,000 children and adolescents. Standardized prevalence was higher in girls (44.6 [95% CI 41.8-47.5] per 100,000), in patients aged 15-17 years (113.7 [95% CI 106.4-121.4] per 100,000), and among African Americans (78.7 [95% CI 71.0-86.9] per 100,000). Highest prevalence of HS was observed among female adolescents aged 15-17 years who were African Americans (525.1 [95% CI 459.4-597.5] per 100,000) and biracial (253.2 [95% CI 121.4-465.6] per 100,000). Patients with HS who went undiagnosed were not captured, and as such prevalence estimates may be underestimated. HS appears to be a postpubertal disease that disproportionately afflicts girls and African Americans in the pediatric population.

A pediatric dermatology expert working group performed a narrative review to describe care related to congenital melanocytic nevi (CMN) in neonates and infants. There are no published guidelines for most aspects of care, including routine skin care and visit intervals. Few guidelines exist for surgical management; newer recommendations favor conservative practice. Emerging evidence contributes to recommendations for screening MRI to evaluate for neural melanosis and related central nervous system complications, however, more research is needed. Risk for melanoma is generally low, but those with large, giant, or multiple CMN have a higher risk. Multidisciplinary care, with a focus on family and patient preferences, is of paramount importance. Without standardized screening and management guidelines, questions abound regarding appropriate physical examination intervals, potential treatment including full or partial excision, timing and frequency of imaging, melanoma risk, and assessment for neural melanosis. This review highlights the current state of knowledge concerning care of patients with CMN, reveals gaps in the literature surrounding skin care, and provides management recommendations. We additionally discuss cutaneous complications of CMN, such as pruritus, hypertrichosis, and wound healing. Resources and references for families and providers can help patients navigate this sometimes challenging diagnosis. Finally, we contribute expert care recommendations to the current body of literature as a foundation for the development of future, more comprehensive care guidelines.

No abstract

Vemurafenib is increasingly being used to treat nonmelanoma tumors that are positive for the BRAF V600E mutation. We report three children who presented with panniculitis induced by vemurafenib while undergoing treatment for central nervous system tumors and review the literature.

Mycoplasma pneumoniae (Mp) is a common cause of respiratory infections, which are accompanied by mucocutaneous manifestations in 20%-30% of cases. 1 These include Mycoplasma pneumoniae-induced rash and mucositis (MIRM), a condition distinct from the syndromes of erythema multiforme (EM) and Stevens-Johnson Syndrome (SJS) in terms of pathophysiology, presentation, treatment, and outcomes. 2 MIRM occurs secondary to an active Mp infection with prodromal symptoms of cough,